- Home
- HRMY vs KRP Comparison
HRMY vs KRP Comparison
Compare HRMY & KRP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HRMY | KRP |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.3B |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | HRMY | KRP |
|---|---|---|
| Price | $28.56 | $14.70 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 5 |
| Target Price | ★ $46.70 | $15.25 |
| AVG Volume (30 Days) | ★ 1.1M | 550.2K |
| Earning Date | 05-18-2026 | 05-29-2026 |
| Dividend Yield | N/A | ★ 10.78% |
| EPS Growth | ★ 7.97 | N/A |
| EPS | ★ 2.71 | N/A |
| Revenue | ★ $868,453,000.00 | $333,830,000.00 |
| Revenue This Year | $18.83 | N/A |
| Revenue Next Year | $12.69 | $8.52 |
| P/E Ratio | $10.70 | ★ N/A |
| Revenue Growth | ★ 21.51 | 7.93 |
| 52 Week Low | $25.52 | $10.98 |
| 52 Week High | $40.87 | $15.12 |
Technical Indicators
Market Signals| Indicator | HRMY | KRP |
|---|---|---|
| Relative Strength Index (RSI) | 31.12 | 70.74 |
| Support Level | $26.36 | $13.50 |
| Resistance Level | $37.98 | $15.10 |
| Average True Range (ATR) | 1.89 | 0.36 |
| MACD | -0.55 | -0.00 |
| Stochastic Oscillator | 21.93 | 94.44 |
Price Performance
Historical ComparisonAbout HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About KRP Kimbell Royalty Partners
Kimbell Royalty Partners LP owns and acquires mineral and royalty interests in oil and natural gas properties throughout the United States. The company's basins and producing regions include areas of interest in the Permian Basin, Mid-Continent, Terryville/Cotton Valley/Haynesville, Appalachian Basin, Eagle Ford, Bakken/Williston Basin, and DJ Basin/Rockies/Niobrara. Its revenues are derived from royalty payments received from operators based on the sale of oil, natural gas and NGL production, as well as the sale of NGLs that are extracted from natural gas during processing.